{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:07:31Z","timestamp":1793747251104,"version":"4.6.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2023AFB457"],"award-info":[{"award-number":["2023AFB457"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204214"],"award-info":[{"award-number":["82204214"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304310"],"award-info":[{"award-number":["82304310"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22363002"],"award-info":[{"award-number":["22363002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ejmech.2024.117065","type":"journal-article","created":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T15:40:36Z","timestamp":1731858036000},"page":"117065","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Novel potent SOS1 inhibitors containing a tricyclic quinazoline scaffold: A joint view of experiments and simulations"],"prefix":"10.1016","volume":"282","author":[{"given":"Luolong","family":"Qing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengzai","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1982-0431","authenticated-orcid":false,"given":"Silong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejmech.2024.117065_bib1","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/2159-8290.CD-21-1331","article-title":"Expanding the reach of precision oncology by drugging All KRAS mutants","volume":"12","author":"Hofmann","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2024.117065_bib2","doi-asserted-by":"crossref","DOI":"10.1007\/s11030-023-10777-6","article-title":"An overview of recent advancements in small molecules suppression of oncogenic signaling of K-RAS: an updated review","author":"Sabt","year":"2024","journal-title":"Mol. Divers."},{"key":"10.1016\/j.ejmech.2024.117065_bib3","article-title":"From bench to bedside: current development and emerging trend of KRAS-targeted therapy","author":"Chen","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"issue":"8","key":"10.1016\/j.ejmech.2024.117065_bib4","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","article-title":"Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS\u2013MAPK reactivation","volume":"11","author":"Tanaka","year":"2021","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.ejmech.2024.117065_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41556-022-01049-w","article-title":"Multiplexed screens identify RAS paralogues HRAS and NRAS as suppressors of KRAS-driven lung cancer growth","volume":"25","author":"Tang","year":"2023","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejmech.2024.117065_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.107092","article-title":"Multiple medicinal chemistry strategies of targeting KRAS: state-of-the art and future directions","volume":"144","author":"Shang","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2024.117065_bib7","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1080\/13543776.2021.1952984","article-title":"Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature","volume":"31","author":"Thompson","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"issue":"4","key":"10.1016\/j.ejmech.2024.117065_bib8","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1039\/D4MD00063C","article-title":"Discovery of novel SOS1 inhibitors using machine learning","volume":"15","author":"Duo","year":"2024","journal-title":"RSC Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2024.117065_bib9","doi-asserted-by":"crossref","first-page":"7130","DOI":"10.1021\/acs.jmedchem.3c02433","article-title":"Discovery of a potent dual son of sevenless 1 (SOS1) and epidermal growth factor receptor (EGFR) inhibitor for the treatment of prostate cancer","volume":"67","author":"Zheng","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117065_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115828","article-title":"Inhibition of son of sevenless homologue 1 (SOS1): promising therapeutic treatment for KRAS-mutant cancers","volume":"261","author":"Chen","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2024.117065_bib11","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1021\/acs.jmedchem.2c01729","article-title":"Development of son of sevenless homologue 1 (SOS1) modulators to treat cancers by regulating RAS signaling","volume":"66","author":"Luo","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117065_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116282","article-title":"Current advances and development strategies of targeting son of sevenless 1 (SOS1) in drug discovery","volume":"268","author":"Wu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2024.117065_bib13","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1073\/pnas.1812963116","article-title":"Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS\u2013SOS1 interaction","volume":"116","author":"Hillig","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.ejmech.2024.117065_bib14","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1158\/2159-8290.CD-20-0142","article-title":"BI-3406, a potent and selective SOS1\u2013KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition","volume":"11","author":"Hofmann","year":"2021","journal-title":"Cancer Discov."},{"issue":"14","key":"10.1016\/j.ejmech.2024.117065_bib15","doi-asserted-by":"crossref","first-page":"9678","DOI":"10.1021\/acs.jmedchem.2c00741","article-title":"Design and discovery of MRTX0902, a potent, selective, brain-penetrant, and orally bioavailable inhibitor of the SOS1:KRAS protein\u2013protein interaction","volume":"65","author":"Ketcham","year":"2022","journal-title":"J. Med. Chem."},{"issue":"19","key":"10.1016\/j.ejmech.2024.117065_bib16","doi-asserted-by":"crossref","first-page":"13158","DOI":"10.1021\/acs.jmedchem.2c00986","article-title":"Discovery of orally bioavailable SOS1 inhibitors for suppressing KRAS-driven carcinoma","volume":"65","author":"He","year":"2022","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.ejmech.2024.117065_bib17","doi-asserted-by":"crossref","first-page":"15856","DOI":"10.1021\/acs.jmedchem.2c01517","article-title":"Design and structural optimization of orally bioavailable SOS1 inhibitors for the treatment of KRAS-driven carcinoma","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117065_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106536","article-title":"Design of Orally-bioavailable Tetra-cyclic phthalazine SOS1 inhibitors with high selectivity against EGFR","volume":"136","author":"He","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"24","key":"10.1016\/j.ejmech.2024.117065_bib19","doi-asserted-by":"crossref","first-page":"16432","DOI":"10.1021\/acs.jmedchem.2c01300","article-title":"Development of SOS1 inhibitor-based degraders to target KRAS-mutant colorectal cancer","volume":"65","author":"Bian","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117065_bib20","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.3c02135","article-title":"Discovery of potent SOS1 PROTACs with effective antitumor activities against NCI-H358 tumor cells in vitro\/in vivo","author":"Pang","year":"2024","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2024.117065_bib21","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1021\/acs.jmedchem.1c01774","article-title":"Discovery of the first-in-class agonist-based SOS1 PROTACs effective in human cancer cells harboring various KRAS mutations","volume":"65","author":"Zhou","year":"2022","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2024.117065_bib22","doi-asserted-by":"crossref","first-page":"6566","DOI":"10.1021\/acs.jmedchem.1c00698","article-title":"Breaking oncogene addiction: getting RTK\/RAS-Mutated cancers off the SOS","volume":"64","author":"Sheffels","year":"2021","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2024.117065_bib23","doi-asserted-by":"crossref","first-page":"6569","DOI":"10.1021\/acs.jmedchem.0c01949","article-title":"One atom makes All the difference: getting a foot in the door between SOS1 and KRAS","volume":"64","author":"Ramharter","year":"2021","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/j.ejmech.2024.117065_bib24","doi-asserted-by":"crossref","first-page":"13841","DOI":"10.1021\/acs.jmedchem.1c01227","article-title":"Discovery of a novel Fusarium graminearum mitogen-activated protein kinase (FgGpmk1) inhibitor for the treatment of Fusarium head blight","volume":"64","author":"Fu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117065_bib25","first-page":"364","article-title":"AIEgen based turn-on fluorescent probes of histone deacetylase 6 via restriction of molecular motion","author":"Li","year":"2022","journal-title":"Sensor. Actuator. B Chem."},{"key":"10.1016\/j.ejmech.2024.117065_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115354","article-title":"Multicomponent Petasis reaction for the identification of pyrazine based multi-target directed anti-Alzheimer's agents: in-silico design, synthesis, and characterization","volume":"254","author":"Madhav","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"20","key":"10.1016\/j.ejmech.2024.117065_bib27","doi-asserted-by":"crossref","first-page":"6183","DOI":"10.1021\/acs.jcim.3c01153","article-title":"AmberTools","volume":"63","author":"Case","year":"2023","journal-title":"J. Chem. Inf. Model."},{"issue":"9","key":"10.1016\/j.ejmech.2024.117065_bib28","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s00894-010-0650-7","article-title":"An improved generalized AMBER force field (GAFF) for urea","volume":"16","author":"\u00d6zp\u0131nar","year":"2010","journal-title":"J. Mol. Model."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424009474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424009474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:07:08Z","timestamp":1777529228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424009474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":28,"alternative-id":["S0223523424009474"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117065","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel potent SOS1 inhibitors containing a tricyclic quinazoline scaffold: A joint view of experiments and simulations","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117065"}}